Rates of<i>ERBB2</i>Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an<i>ERBB2</i>-Amplified Acral Melanoma

Abstract

<i>ERBB2</i> amplification is present in a minority of acral lentiginous and mucosal melanomas. Activating mutations in <i>ERBB2</i> were identified in nonuveal melanoma subtypes and are frequently comutated with canonical drivers. HER2 could represent a therapeutically relevant target across melanoma subtypes.